Advanced Cell Diagnostics (ACD) achieves
significant global customer adoption milestone
MINNEAPOLIS, April 8,
2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced that Advanced Cell Diagnostics (ACD), part of
Bio-Techne's Spatial Biology Division, has surpassed 10,000
peer-reviewed publications referencing the use and application of
RNAscope™ ISH technology. Over 50% of these publications
were released in the past 3 years, as increasing global customer
awareness and expanded market adoption solidify ACD's leadership in
spatial biology applications.
As a pioneer in spatial biology, Bio-Techne's broad portfolio of
over 50,000 unique RNAscope™ ISH probes across over 400
species enables its biopharma and academic customers to reveal
ground-breaking biologic discoveries, accelerate the development of
next generation therapeutics, and deliver life-changing
diagnostics. Representing the most referenced spatial biology
technology in the industry for RNA biomarkers, RNAscope™
offers best-in-class single-molecule sensitivity with unrivaled
specificity at subcellular resolution. This landmark portfolio of
10,000 scientific publications encompasses applications in
cancer and neuroscience, as well as additional areas of research
including immunology, infectious disease, cell and gene
therapy, and regenerative medicine.
"We are thrilled to celebrate the achievement of over 10,000
publications referencing RNAscope™ ISH technology," said
Matt McManus, President of
Bio-Techne's Diagnostics & Genomics Segment. "We are honored by
the trust the scientific community has placed in
RNAscope™ to uncover new spatial insights and enable
significant breakthroughs across a wide range of diseases."
About Bio-Techne Corporation
Bio-Techne
Corporation (NASDAQ: TECH) is a global life sciences company
providing innovative tools and bioactive reagents for the research
and clinical diagnostic communities. Bio-Techne products assist
scientific investigations into biological processes and the nature
and progress of specific diseases. They aid in drug discovery
efforts and provide the means for accurate clinical tests and
diagnoses. With thousands of products in its portfolio, Bio-Techne
generated over $1.1 billion in net
sales in fiscal 2023 and has approximately 3,100 employees
worldwide. For more information on Bio-Techne and its brands,
please visit https://www.bio-techne.com or follow the
Company on social media
at: Facebook, LinkedIn, Twitter or YouTube.
Bio-Techne Investor Contact:
David Clair,
Vice President, Investor Relations and Corporate Development
612-656-4416
David.clair@bio-techne.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-surpasses-10-000-peer-reviewed-publications-citing-rnascope-technology-302109757.html
SOURCE Bio-Techne Corporation